Genome-wide approaches to antidepressant treatment: working towards understanding and predicting response

Table 3 Genome-wide association studies of antidepressant treatment response

Sample	GWAS sample size (N)	Microarray used	Primary outcome measure	Response phenotype definition	SNPs reaching suggestive levels of significance (nearest gene)
STAR*D [5]	1,948	Affymetrix 500K/5.0 human SNP arrays	QID-SR	Response: >50% reduction in score	rs6966038 (UBE3C), rs6127921 (BMP7), rs809736 (RORA)
				Remission: score <5
MARS [9]	339 (two replication samples, N=361 and N=831)	Sentrix Human-1 and HumanHap300 BeadChip	HAM-D	Early partial response: >25% reduction in score after 2 weeks of treatment	rs6989467 (CDH17)^a, rs1502174 (EPHB1)
				Response: >50% reduction in score
				Remission: score <10
GENDEP [13]	706	Illumina 610 array	MADRS	Percentage change from baseline to week 12	Whole-sample analysis	rs2136093, rs6701608 and rs2136094 (intergenic, on chromosome 1)rs16920624, rs11598854 and rs7081156 (intergenic, on chromosome 10)
					Escitalopram-specific analysis	rs1126757 (IL11)
					Nortriptyline-specific analysis	rs2500535 (UST)
					Gene-by-drug analysis	rs2500535 (UST)

^aOnly associated with early partial response. GWAS, genome-wide association study; HAM-D, Hamilton Depression Rating Scale; MADRS, Montgomery-Asberg Depression Rating scale; QID-SR, Quick Inventory of Depressive Symptomatology Self-Report version; SNP, single nucleotide polymorphism.

ISSN: 1756-994X